Executive Summary
The overnight filing period reveals a significant cluster of insider selling activity, particularly concentrated in CoreWeave, Spyre Therapeutics, and ASP Isotopes, raising caution flags for these names. A major capital return event is unfolding at Janus Henderson, with two directors disposing of over $50M in stock back to the issuer, signaling a potential large-scale buyback or restructuring.
The most impactful corporate action is the announced merger between Passage BIO and Remix Therapeutics, creating a new entity (RMTX) and offering a contingent value right to existing PASG shareholders, which represents a high-conviction catalyst. Period-over-period trends are limited in this filing set, but the insider trading patterns show a clear bearish tilt, with 14 negative transactions versus only 1 positive purchase. The data suggests a defensive posture among corporate insiders in growth and biotech names, while financial and utility sectors show routine, non-alarming insider activity. Overall, the digest points to heightened risk in high-growth names and a potential opportunity in the Passage BIO/Remix merger arbitrage.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Form 4 · Schedule 13G · Schedule 13D
Tracking the trend? Catch up on the prior US Pre-Market SEC Filings Roundup digest from June 26, 2026.
Investment Signals (10)
- CoreWeave ↓ (BEARISH)▲
CEO Intrator sold $7.52M and CSO Venturo sold $6.27M, both under 10b5-1 plans, representing a combined $13.8M in insider selling. This is a massive signal of potential overvaluation or insider desire to lock in gains post-IPO.
- Spyre Therapeutics ↓ (BEARISH)▲
CEO Turtle Cameron sold $890K, CFO Burrows sold $506K, and CMO Sloan sold $569K, all under 10b5-1 plans. Total insider selling of ~$1.96M at ~$87.50, while options were exercised at ~$14.50-$27.46, indicating a massive profit-taking event.
- Janus Henderson ↓ (BULLISH)▲
Two directors (Baldwin and Frank) disposed of a combined 1,036,354 shares back to the issuer at $52.00, totaling ~$53.9M. This is a strong signal of a significant capital return or buyback program, which is bullish for remaining shareholders.
- Passage BIO ↓ (BULLISH)▲
Lynx1 Capital crossed the 20% ownership threshold (now 21.0%) and disclosed a merger with Remix Therapeutics. The concurrent financing and contingent value rights create a high-upside catalyst for existing PASG holders.
- Fermi Inc. ↓ (BEARISH)▲
Director Perry sold 863,637 shares for ~$6.31M at $7.31. This is a large, unscheduled sale by a director, suggesting a lack of confidence or a need for liquidity, which is a bearish signal for the stock.
- STRATUS PROPERTIES ↓ (BEARISH)▲
10% owner Oasis Management sold 117,612 shares for ~$3.3M at $28.03. This is a significant reduction by a major activist investor, signaling potential disappointment with the company's trajectory or valuation.
- ASP Isotopes ↓ (BEARISH)▲
EVP Ainscow sold 100,000 shares for $614K and CFO Kiessling sold 23,124 shares for $145K. Combined insider selling of ~$759K at ~$6.20, with no insider buying, indicating a bearish outlook from management.
- ▲
10% owner Saba Capital sold 224,000 shares for ~$3.53M at ~$15.74. This is a notable reduction by a well-known activist, suggesting the trust may be overvalued or that Saba is rotating capital.
- Navan, Inc. ↓ (BEARISH)▲
10% owner Lightspeed Venture Partners sold 21,138 shares for ~$522K at $24.65. While not massive, it is a sale by a prominent VC, which can be a signal of early-stage profit-taking.
- Grab Holdings ↓ (NEUTRAL)▲
CFO Oey and CEO Tan were both awarded 3,305 shares each at $3.20, a routine compensation event. However, Chief Org Capability Officer Ong sold 38,000 shares at $3.88 under a 10b5-1 plan, a mixed signal.
Risk Flags (8)
- CoreWeave / Insider Selling Cluster↓ [HIGH RISK]▼
CEO, CSO, COO, CFO, and other executives all sold shares, with total insider selling exceeding $14M. This is a massive red flag for a recent IPO, suggesting insiders are aggressively reducing exposure.
- Spyre Therapeutics / Insider Profit-Taking↓ [HIGH RISK]▼
Three top executives (CEO, CFO, CMO) sold shares after exercising low-cost options. The stock is trading near $87, and the exercise prices were $14.50-$27.46, indicating a 3x-6x gain. This level of coordinated selling suggests the stock may be near a peak.
- Fermi Inc. / Large Director Sale↓ [HIGH RISK]▼
Director Perry sold 863,637 shares in a single transaction, representing a significant portion of his holdings. No explanation or 10b5-1 plan was noted, which is a major governance risk.
- STRATUS PROPERTIES / Activist Exit↓ [MEDIUM RISK]▼
10% owner Oasis Management sold $3.3M worth of stock. If this is the start of a larger exit, it could pressure the stock further.
- ASP Isotopes / Insider Selling↓ [MEDIUM RISK]▼
EVP sold 100,000 shares and CFO sold 23,124 shares. With no insider buying, this signals a lack of confidence in the near-term outlook.
-
Saba Capital, a known activist, sold $3.53M in shares. This could indicate they are losing conviction or see better opportunities elsewhere.
- Navan, Inc. / VC Selling↓ [LOW RISK]▼
Lightspeed Venture Partners sold shares. While VC selling is common, it can be a negative signal for a pre-IPO or growth-stage company.
- Better Home & Finance / CFO Tax Withholding↓ [LOW RISK]▼
CFO Advani had shares withheld for taxes, which is routine. However, the stock price of $30.19 is high relative to the sector, and any insider selling (even tax-related) can be a signal.
Opportunities (8)
- Passage BIO / Remix Merger Arbitrage↓ (OPPORTUNITY)◆
The merger with Remix Therapeutics creates a new entity (RMTX) and offers contingent value rights to existing PASG holders. With Lynx1 Capital increasing its stake to 21.0%, there is a strong alignment of interests. This is a high-conviction catalyst for a special situation.
- Janus Henderson / Capital Return Event↓ (OPPORTUNITY)◆
Two directors disposed of $53.9M in stock back to the issuer at $52.00. This is a strong signal of a potential large-scale buyback or tender offer, which could drive the stock price higher.
- HUMANA / Director Award↓ (OPPORTUNITY)◆
Director HILZINGER was awarded 233 RSUs at $392.32. While small, this is a routine compensation event that aligns director interests with shareholders. The stock is in the healthcare sector, which may be a defensive play.
- NEW GERMANY FUND / Insider Buying↓ (OPPORTUNITY)◆
10% owner Saba Capital bought 100 shares at $11.37. While a tiny purchase, it is the only insider buying in the entire digest and could signal a bottom in the fund's price.
- CYPHERPUNK TECHNOLOGIES / Director Award↓ (OPPORTUNITY)◆
Director Richard was awarded 75,000 RSUs, a significant grant that aligns management with long-term performance. This could be a turnaround story.
- Nuo Therapeutics / Insider Options Exercise↓ (OPPORTUNITY)◆
CEO JORDEN and directors exercised options at $1.00, with shares withheld for taxes. This shows they are willing to invest their own capital, which is a positive signal for a micro-cap.
- HAWAIIAN ELECTRIC INDUSTRIES / Director Awards↓ (OPPORTUNITY)◆
Five directors were each awarded 9,238 shares, a routine grant that aligns interests. The utility sector is a defensive play, and the stock may be a safe haven in a volatile market.
- KEYCORP / Director Awards↓ (OPPORTUNITY)◆
Four directors were awarded deferred shares, a routine compensation event. KeyCorp is a regional bank, and this could be a value play if the sector recovers.
Sector Themes (5)
- Insider Selling Dominates Growth Names◆
Across the digest, 14 negative insider transactions (sales) were reported versus only 1 positive purchase. This is a clear bearish signal for growth and biotech names, suggesting insiders are taking profits or reducing exposure. The most concentrated selling was in CoreWeave, Spyre Therapeutics, and ASP Isotopes.
- Capital Return Activity in Financials◆
Janus Henderson's $53.9M director disposition back to the issuer is a standout event. This suggests that financial firms with strong balance sheets may be returning capital to shareholders, a bullish theme for the sector.
- M&A Catalyst in Biotech◆
The Passage BIO/Remix merger is the only M&A event in the digest, but it is a high-impact one. The creation of a new entity (RMTX) and contingent value rights for existing shareholders is a unique catalyst that could drive significant returns.
- Routine Compensation Awards in Utilities and Banks◆
Hawaiian Electric and KeyCorp both reported routine director stock awards. This is a neutral signal but indicates that these sectors are in a steady-state, with no insider alarm bells. This contrasts sharply with the selling in growth names.
- Activist Activity in Closed-End Funds◆
Saba Capital was active in both BlackRock ESG Capital Allocation Term Trust (selling) and NEW GERMANY FUND (buying). This suggests Saba is rotating capital within the closed-end fund space, which could create opportunities for nimble investors.
Watch List (8)
- Passage BIO / Remix Merger↓ (HIGH PRIORITY)👁
The merger is expected to close soon, with the combined company trading under RMTX. Watch for the final approval and the value of the contingent rights.
- CoreWeave / Insider Selling↓ (HIGH PRIORITY)👁
With CEO and CSO selling heavily, watch for further insider filings. If the selling continues, it could signal a major top in the stock.
- Spyre Therapeutics / Insider Selling↓ (HIGH PRIORITY)👁
The coordinated selling by three top executives is a red flag. Watch for any insider buying or positive news to reverse the sentiment.
- Janus Henderson / Capital Return↓ (MEDIUM PRIORITY)👁
The $53.9M disposition suggests a buyback or tender offer. Watch for a formal announcement, which could be a catalyst for the stock.
- STRATUS PROPERTIES / Oasis Management↓ (MEDIUM PRIORITY)👁
With Oasis selling, watch for further 13D filings or a change in activist strategy.
- ASP Isotopes / Insider Selling↓ (MEDIUM PRIORITY)👁
The EVP and CFO sales are concerning. Watch for any operational updates or insider buying to restore confidence.
- Fermi Inc. / Director Sale↓ (MEDIUM PRIORITY)👁
The large director sale is a red flag. Watch for any company announcements or further insider activity.
- BlackRock ESG Capital Allocation Term Trust / Saba Capital↓ (LOW PRIORITY)👁
Saba's selling could be a signal of a broader trend in the CEF space. Watch for further filings.
Filing Analyses
(50)
02-07-2026
Director WINZER C ERIC had withheld for taxes 39,604 Common Stock at $1.01 (~$40K). 4 transactions reported in total. WINZER C ERIC holds 173,050 shares after the transaction.
- · Director WINZER C ERIC exercised/converted 40,000 Common Stock at $1.00 (~$40K)
- · Director WINZER C ERIC had withheld for taxes 39,604 Common Stock at $1.01 (~$40K)
- · Director WINZER C ERIC exercised/converted 40,000 Option to purchase common stock
- · Director WINZER C ERIC was awarded 30,000 Option to purchase common stock
02-07-2026
Director Mintz Paul was awarded 30,000 Option to Purchase Common Stock.
- · Director Mintz Paul was awarded 30,000 Option to Purchase Common Stock
02-07-2026
Director KANE MICAH A. was awarded 9,238 Common Stock. KANE MICAH A. holds 41,514.72 shares after the transaction.
- · Director KANE MICAH A. was awarded 9,238 Common Stock
02-07-2026
Director HILZINGER KURT J was awarded 233 Restricted Stock Units at $392.32 (~$91.4K).
- · Director HILZINGER KURT J was awarded 233 Restricted Stock Units at $392.32 (~$91.4K)
02-07-2026
Director Flores Elisia was awarded 9,238 Common Stock. Flores Elisia holds 33,996 shares after the transaction.
- · Director Flores Elisia was awarded 9,238 Common Stock
02-07-2026
Director Perry James Richard sold 863,637 Common Stock at $7.31 (~$6.31M). Perry James Richard holds 15,827,807 shares after the transaction.
- · Director Perry James Richard sold 863,637 Common Stock at $7.31 (~$6.31M)
02-07-2026
Director FOWLER PEGGY Y was awarded 9,238 Common Stock. FOWLER PEGGY Y holds 9,238 shares after the transaction.
- · Director FOWLER PEGGY Y was awarded 9,238 Common Stock
02-07-2026
Chief Financial Officer Oey Peter Henry was awarded 3,305 Class A Ordinary Shares at $3.20 (~$10.6K). Oey Peter Henry holds 6,953,470 shares after the transaction.
- · Chief Financial Officer Oey Peter Henry was awarded 3,305 Class A Ordinary Shares at $3.20 (~$10.6K)
02-07-2026
Chief Executive Officer Tan Anthony Ping Yeow was awarded 3,305 Class A Ordinary Shares at $3.20 (~$10.6K). Tan Anthony Ping Yeow holds 428,498 shares after the transaction.
- · Chief Executive Officer Tan Anthony Ping Yeow was awarded 3,305 Class A Ordinary Shares at $3.20 (~$10.6K)
02-07-2026
Director Ajello James A was awarded 9,238 Common Stock. Ajello James A holds 9,238 shares after the transaction.
- · Director Ajello James A was awarded 9,238 Common Stock
02-07-2026
Director O CONNOR KEVIN J sold 5,769 Common Stock at $41.93 (~$242K). O CONNOR KEVIN J holds 962,132 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Director O CONNOR KEVIN J sold 5,769 Common Stock at $41.93 (~$242K)
- · Director O CONNOR KEVIN J sold 1,697 Common Stock at $42.40 (~$72K)
- · Director O CONNOR KEVIN J sold 4,072 Common Stock at $42.99 (~$175K)
02-07-2026
Chief Financial Officer Advani Loveen had withheld for taxes 2,510 Class A Common Stock at $30.19 (~$75.8K). 6 transactions reported in total. Advani Loveen holds 13,824 shares after the transaction.
- · Chief Financial Officer Advani Loveen exercised/converted 9,167 Class A Common Stock
- · Chief Financial Officer Advani Loveen had withheld for taxes 2,510 Class A Common Stock at $27.48 (~$69K)
- · Chief Financial Officer Advani Loveen exercised/converted 9,167 Class A Common Stock
- · Chief Financial Officer Advani Loveen had withheld for taxes 2,510 Class A Common Stock at $30.19 (~$75.8K)
- · Chief Financial Officer Advani Loveen exercised/converted 9,167 Restricted Stock Units (Class A)
- · Chief Financial Officer Advani Loveen exercised/converted 9,167 Restricted Stock Units (Class A)
02-07-2026
Chief Org Capability Officer Ong Chin Yin sold 38,000 Class A Ordinary Shares at $3.88 (~$147K). Ong Chin Yin holds 3,708,611 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Chief Org Capability Officer Ong Chin Yin was awarded 3,305 Class A Ordinary Shares at $3.20 (~$10.6K)
- · Chief Org Capability Officer Ong Chin Yin sold 38,000 Class A Ordinary Shares at $3.88 (~$147K)
02-07-2026
Director Baldwin Brian M disposed to the issuer 518,177 Common Stock at $52.00 (~$26.9M).
- · Director Baldwin Brian M disposed of 25,136,205 Common Stock
- · Director Baldwin Brian M disposed to the issuer 518,177 Common Stock at $52.00 (~$26.9M)
02-07-2026
CEO/CFO JORDEN DAVID EMERSON had withheld for taxes 160,892 Common Stock at $1.01 (~$163K). 4 transactions reported in total. JORDEN DAVID EMERSON holds 2,061,227 shares after the transaction.
- · CEO/CFO JORDEN DAVID EMERSON exercised/converted 162,500 Common Stock at $1.00 (~$163K)
- · CEO/CFO JORDEN DAVID EMERSON had withheld for taxes 160,892 Common Stock at $1.01 (~$163K)
- · CEO/CFO JORDEN DAVID EMERSON exercised/converted 162,500 Option to purchase common stock
- · CEO/CFO JORDEN DAVID EMERSON was awarded 125,000 Option to purchase common stock
02-07-2026
10% owner Saba Capital Management, L.P. sold 130,170 Common Stock at $15.73 (~$2.05M). Saba Capital Management, L.P. holds 17,518,628 shares after the transaction.
- · 10% owner Saba Capital Management, L.P. sold 130,170 Common Stock at $15.73 (~$2.05M)
- · 10% owner Saba Capital Management, L.P. sold 93,821 Common Stock at $15.76 (~$1.48M)
02-07-2026
Director Frank Joshua D. disposed to the issuer 518,177 Common Stock at $52.00 (~$26.9M).
- · Director Frank Joshua D. disposed of 25,136,205 Common Stock
- · Director Frank Joshua D. disposed to the issuer 518,177 Common Stock at $52.00 (~$26.9M)
02-07-2026
Director Taniguchi Toby B. was awarded 9,238 Common Stock. Taniguchi Toby B. holds 25,733 shares after the transaction.
- · Director Taniguchi Toby B. was awarded 9,238 Common Stock
02-07-2026
Director Pittman Scott M. had withheld for taxes 39,604 Common Stock at $1.01 (~$40K). 4 transactions reported in total. Pittman Scott M. holds 5,400,396 shares after the transaction.
- · Director Pittman Scott M. exercised/converted 40,000 Common Stock at $1.00 (~$40K)
- · Director Pittman Scott M. had withheld for taxes 39,604 Common Stock at $1.01 (~$40K)
- · Director Pittman Scott M. exercised/converted 40,000 Option to purchase common stock
- · Director Pittman Scott M. was awarded 30,000 Option to purchase common stock
02-07-2026
Chief Executive Officer Arora Nikesh disposed of 865,090 Phantom Stock.
- · Chief Executive Officer Arora Nikesh disposed of 865,090 Phantom Stock
02-07-2026
Chief Executive Officer Fogassa Marc disposed to the issuer 55,555 Common Stock at $3.64 (~$202K). Fogassa Marc holds 4,991,393 shares after the transaction.
- · Chief Executive Officer Fogassa Marc disposed to the issuer 55,555 Common Stock at $3.64 (~$202K)
02-07-2026
Chief Strategy Officer Venturo Brian M sold 65,493 Class A Common Stock at $95.69 (~$6.27M). 13 transactions reported in total. Venturo Brian M holds 20 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Chief Strategy Officer Venturo Brian M sold 65,493 Class A Common Stock at $95.69 (~$6.27M)
- · Chief Strategy Officer Venturo Brian M sold 13,822 Class A Common Stock at $85.63 (~$1.18M)
- · Chief Strategy Officer Venturo Brian M sold 21,118 Class A Common Stock at $86.60 (~$1.83M)
- · Chief Strategy Officer Venturo Brian M sold 15,524 Class A Common Stock at $87.44 (~$1.36M)
- · Chief Strategy Officer Venturo Brian M sold 7,736 Class A Common Stock at $88.57 (~$685K)
- · Chief Strategy Officer Venturo Brian M sold 3,252 Class A Common Stock at $89.34 (~$291K)
- · Chief Strategy Officer Venturo Brian M sold 80 Class A Common Stock at $90.16 (~$7.21K)
- · Chief Strategy Officer Venturo Brian M sold 3,455 Class A Common Stock at $85.63 (~$296K)
02-07-2026
GC and Secretary McVeety Kristen J sold 4 Class A Common Stock at $95.69 (~$383). McVeety Kristen J holds 121,718 shares after the transaction.
- · GC and Secretary McVeety Kristen J exercised/converted 7 Class A Common Stock
- · GC and Secretary McVeety Kristen J sold 4 Class A Common Stock at $95.69 (~$383)
- · GC and Secretary McVeety Kristen J exercised/converted 7 Restricted Stock Units
02-07-2026
CEO, Chairman of the Board STERNLICHT BARRY S exercised/converted 276,666 Common Stock. STERNLICHT BARRY S holds 3,561,724 shares after the transaction.
- · CEO, Chairman of the Board STERNLICHT BARRY S exercised/converted 276,666 Common Stock
- · CEO, Chairman of the Board STERNLICHT BARRY S exercised/converted 276,666 Restricted Stock Units
02-07-2026
Chief Operating Officer Jain Sachin sold 3 Class A Common Stock at $95.69 (~$287). Jain Sachin holds 127,633 shares after the transaction.
- · Chief Operating Officer Jain Sachin exercised/converted 7 Class A Common Stock
- · Chief Operating Officer Jain Sachin sold 3 Class A Common Stock at $95.69 (~$287)
- · Chief Operating Officer Jain Sachin exercised/converted 7 Restricted Stock Units
02-07-2026
CEO and President Intrator Michael N sold 78,560 Class A Common Stock at $95.69 (~$7.52M). 13 transactions reported in total. Intrator Michael N holds 25,170 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · CEO and President Intrator Michael N sold 78,560 Class A Common Stock at $95.69 (~$7.52M)
- · CEO and President Intrator Michael N sold 6,423 Class A Common Stock at $94.66 (~$608K)
- · CEO and President Intrator Michael N sold 4,692 Class A Common Stock at $95.54 (~$448K)
- · CEO and President Intrator Michael N sold 23,581 Class A Common Stock at $96.84 (~$2.28M)
- · CEO and President Intrator Michael N sold 76,659 Class A Common Stock at $97.77 (~$7.5M)
- · CEO and President Intrator Michael N sold 41,901 Class A Common Stock at $98.69 (~$4.14M)
- · CEO and President Intrator Michael N sold 46,744 Class A Common Stock at $99.54 (~$4.65M)
- · CEO and President Intrator Michael N sold 3,458 Class A Common Stock at $94.66 (~$327K)
02-07-2026
EVP, Product & Engineering Goldberg Chen sold 4 Class A Common Stock at $95.69 (~$383). Goldberg Chen holds 59,371 shares after the transaction.
- · EVP, Product & Engineering Goldberg Chen exercised/converted 7 Class A Common Stock
- · EVP, Product & Engineering Goldberg Chen sold 4 Class A Common Stock at $95.69 (~$383)
- · EVP, Product & Engineering Goldberg Chen exercised/converted 7 Restricted Stock Units
02-07-2026
Chief Technology Officer Paradatheth Suthen Thomas was awarded 3,305 Class A Ordinary Shares at $3.20 (~$10.6K). Paradatheth Suthen Thomas holds 4,383,677 shares after the transaction.
- · Chief Technology Officer Paradatheth Suthen Thomas was awarded 3,305 Class A Ordinary Shares at $3.20 (~$10.6K)
02-07-2026
10% owner Saba Capital Management, L.P. bought 100 Common Stock at $11.37 (~$1.14K). Saba Capital Management, L.P. holds 3,602,815 shares after the transaction.
- · 10% owner Saba Capital Management, L.P. bought 100 Common Stock at $11.37 (~$1.14K)
02-07-2026
Principal Accounting Officer Baker Jeff sold 4 Class A Common Stock at $95.69 (~$383). Baker Jeff holds 1,122 shares after the transaction.
- · Principal Accounting Officer Baker Jeff exercised/converted 7 Class A Common Stock
- · Principal Accounting Officer Baker Jeff sold 4 Class A Common Stock at $95.69 (~$383)
- · Principal Accounting Officer Baker Jeff exercised/converted 7 Restricted Stock Units
02-07-2026
Chief Financial Officer Agrawal Nitin sold 4 Class A Common Stock at $95.69 (~$383). Agrawal Nitin holds 193,774 shares after the transaction.
- · Chief Financial Officer Agrawal Nitin exercised/converted 7 Class A Common Stock
- · Chief Financial Officer Agrawal Nitin sold 4 Class A Common Stock at $95.69 (~$383)
- · Chief Financial Officer Agrawal Nitin exercised/converted 7 Restricted Stock Units
02-07-2026
President and COO Hungate Alexander Charles was awarded 3,305 Class A Ordinary Shares at $3.20 (~$10.6K). Hungate Alexander Charles holds 6,257,328 shares after the transaction.
- · President and COO Hungate Alexander Charles was awarded 3,305 Class A Ordinary Shares at $3.20 (~$10.6K)
02-07-2026
Chief Product Officer Kandal Philipp Wolfgang Josef was awarded 3,305 Class A Ordinary Shares at $3.20 (~$10.6K). Kandal Philipp Wolfgang Josef holds 4,068,735 shares after the transaction.
- · Chief Product Officer Kandal Philipp Wolfgang Josef was awarded 3,305 Class A Ordinary Shares at $3.20 (~$10.6K)
02-07-2026
Christopher Castillo filed a Schedule 13G/A with the SEC on July 2, 2026, reporting beneficial ownership of 62,000 shares of Aditxt, Inc. common stock, representing a 6.2% stake. The filing indicates no change in ownership from the prior reporting period, with the same 62,000 shares held as of June 18, 2026.
- · The filing is an amendment (Schedule 13G/A) to a previous beneficial ownership report.
- · Castillo acquired the shares under Rule 13d-1(c), indicating passive investment intent.
- · The shares were not acquired or held with the purpose of changing or influencing control of the issuer.
02-07-2026
Christopher Castillo filed a Schedule 13G with the SEC on July 2, 2026, reporting beneficial ownership of 75,000 shares of Aditxt, Inc. common stock, representing a 9.19% stake in the company. The filing indicates the shares were acquired on June 17, 2026, and are held for investment purposes without intent to change or influence control of the issuer.
- · The filing is made under Rule 13d-1(c), indicating the shares are held for investment purposes only.
- · Christopher Castillo's sole voting and dispositive power covers all 75,000 shares.
- · The filing date is July 2, 2026, and the event date for the acquisition is June 17, 2026.
- · The beneficial owner's address is 12701 W Catalina Drive, Avondale, AZ 85392.
02-07-2026
Lynx1 Capital Management LP and Weston Nichols filed a Schedule 13D after their beneficial ownership in Passage BIO, Inc. (PASG) crossed the 20% threshold, now holding 673,759 shares (21.0% of 3,212,810 outstanding shares). The filing discloses that on June 24, 2026, Passage BIO entered into a merger agreement with Remix Therapeutics, Inc., with Lynx1 participating in a concurrent financing to purchase Remix common stock and convertible notes. The combined company will be renamed Remix Therapeutics and trade under the symbol RMTX, while existing Passage BIO stockholders will receive contingent value rights.
- · The Reporting Persons previously reported ownership on Schedule 13G under Rule 13d-1(c) but are no longer eligible due to crossing the 20% threshold.
- · The most recent open-market purchase of 50,055 shares occurred on June 25, 2026 at a weighted average price of $4.1175 per share (range $3.33–$4.30).
- · The Concurrent Financing is conditioned on the satisfaction or waiver of certain conditions to the Merger.
- · The Reporting Persons reserve the right to increase or decrease their position, enter into derivative transactions, or adjust economic exposure without affecting beneficial ownership.
- · The CVR Agreement will entitle each record holder of Common Stock to receive one contingent value right per share held as of the last business day prior to the Effective Time.
02-07-2026
Chief Financial Officer Burrows Scott L sold 5,775 Common Stock at $87.55 (~$506K). 4 transactions reported in total. Burrows Scott L holds 97,994 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Chief Financial Officer Burrows Scott L exercised/converted 7,500 Common Stock at $14.50 (~$109K)
- · Chief Financial Officer Burrows Scott L sold 5,775 Common Stock at $87.55 (~$506K)
- · Chief Financial Officer Burrows Scott L sold 1,725 Common Stock at $88.37 (~$152K)
- · Chief Financial Officer Burrows Scott L exercised/converted 7,500 Stock Option (Right to Buy)
02-07-2026
Chief Medical Officer Sloan Sheldon sold 6,500 Common Stock at $87.52 (~$569K). 4 transactions reported in total. Sloan Sheldon holds 1,834 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Chief Medical Officer Sloan Sheldon exercised/converted 8,334 Common Stock at $27.46 (~$229K)
- · Chief Medical Officer Sloan Sheldon sold 6,500 Common Stock at $87.52 (~$569K)
- · Chief Medical Officer Sloan Sheldon sold 1,834 Common Stock at $88.34 (~$162K)
- · Chief Medical Officer Sloan Sheldon exercised/converted 8,334 Stock Option (Right to Buy)
02-07-2026
Chief Executive Officer Turtle Cameron sold 10,176 Common Stock at $87.44 (~$890K). Turtle Cameron holds 582,540 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Chief Executive Officer Turtle Cameron sold 10,176 Common Stock at $87.44 (~$890K)
- · Chief Executive Officer Turtle Cameron sold 4,234 Common Stock at $88.12 (~$373K)
- · Chief Executive Officer Turtle Cameron sold 590 Common Stock at $88.91 (~$52.5K)
02-07-2026
10% owner Lightspeed Venture Partners X, L.P. sold 10,569 Class A Common Stock at $24.65 (~$261K).
- · 10% owner Lightspeed Venture Partners X, L.P. sold 10,569 Class A Common Stock at $24.65 (~$261K)
02-07-2026
CSO/COO CLAUSEN PETER was awarded 65,000 Option to purchase common stock.
- · CSO/COO CLAUSEN PETER was awarded 65,000 Option to purchase common stock
02-07-2026
10% owner Oasis Management Co Ltd. sold 117,612 Common Stock, par value $0.01 per share at $28.03 (~$3.3M). Oasis Management Co Ltd. holds 843,517 shares after the transaction.
- · 10% owner Oasis Management Co Ltd. sold 10,000 Common Stock, par value $0.01 per share at $28.90 (~$289K)
- · 10% owner Oasis Management Co Ltd. sold 117,612 Common Stock, par value $0.01 per share at $28.03 (~$3.3M)
02-07-2026
Director VASOS TODD J was awarded 1,843 Deferred Shares.
- · Director VASOS TODD J was awarded 1,843 Deferred Shares
02-07-2026
Director Rankin Devina A was awarded 1,355 Deferred Shares.
- · Director Rankin Devina A was awarded 1,355 Deferred Shares
02-07-2026
Chief Financial Officer Kiessling Heather sold 23,124 Common Stock at $6.28 (~$145K). Kiessling Heather holds 1,526,252 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Chief Financial Officer Kiessling Heather sold 23,124 Common Stock at $6.28 (~$145K)
02-07-2026
Director Hayes Robin was awarded 1,355 Deferred Shares.
- · Director Hayes Robin was awarded 1,355 Deferred Shares
02-07-2026
EVP, Gen Counsel, Secretary Ainscow Donald George sold 100,000 Common Stock at $6.14 (~$614K). Ainscow Donald George holds 800,000 shares after the transaction.
- · EVP, Gen Counsel, Secretary Ainscow Donald George sold 100,000 Common Stock at $6.14 (~$614K)
02-07-2026
Director CUTLER ALEXANDER M was awarded 732 Deferred Shares.
- · Director CUTLER ALEXANDER M was awarded 732 Deferred Shares
02-07-2026
Director Richard Christian M was awarded 75,000 Restricted Stock Units.
- · Director Richard Christian M was awarded 75,000 Restricted Stock Units
Get daily alerts with 10 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 50 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US Pre-Market SEC Filings Roundup
🇺🇸 More from United States
View all →June 25, 2026
US Activist Hedge Fund Institutional SEC 13D 13G — June 25, 2026
US Activist Hedge Fund Institutional SEC 13D 13G
June 25, 2026
S&P 500 Energy Sector SEC Filings — June 25, 2026
S&P 500 Energy Sector SEC Filings
June 25, 2026
S&P 500 Healthcare Sector SEC Filings — June 25, 2026
S&P 500 Healthcare Sector SEC Filings
June 25, 2026
US IPO Pipeline SEC S-1 Filings — June 25, 2026
US IPO Pipeline SEC S-1 Filings